Cinven-owned international lab group Synlab will reportedly launch an IPO in April with roadshow presentations being held this week. But how do you fairly value a business which is getting 20-30% of its revenues from COVID-19 testing, and what is happening in Switzerland where big write-downs drove a group net loss in the first nine months? We talk to market sources.
The post Synlab to launch IPO in spring but valuation conundrum remains appeared first on Healthcare Business International.
